×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RCUS – arcus biosciences, inc. (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RCUS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/27
10:25 am
rcus
Arcus Biosciences: TIGIT In The Rearview Mirror, But Market Pricing A Bit Too Aggressively For Now [Seeking Alpha]
Medium
Report
Arcus Biosciences: TIGIT In The Rearview Mirror, But Market Pricing A Bit Too Aggressively For Now [Seeking Alpha]
4/25
05:23 am
rcus
Arcus Biosciences (RCUS) Is Up 5.2% After Lung Trial Futility Results And Gilead Option Shift [Yahoo! Finance]
Medium
Report
Arcus Biosciences (RCUS) Is Up 5.2% After Lung Trial Futility Results And Gilead Option Shift [Yahoo! Finance]
4/24
04:05 pm
rcus
Arcus Biosciences Announces New Employment Inducement Grants
Low
Report
Arcus Biosciences Announces New Employment Inducement Grants
4/21
04:05 pm
rcus
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates
Medium
Report
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates
4/20
04:02 pm
rcus
Arcus Biosciences (RCUS) was given a new $47.00 price target by Leerink Partners.
Medium
Report
Arcus Biosciences (RCUS) was given a new $47.00 price target by Leerink Partners.
4/9
04:35 pm
rcus
Arcus Biosciences Announces New Employment Inducement Grants
Medium
Report
Arcus Biosciences Announces New Employment Inducement Grants
4/2
09:00 am
rcus
Arcus Biosciences (RCUS) had its price target raised by Wedbush from $37.00 to $41.00. They now have an "outperform" rating on the stock.
Medium
Report
Arcus Biosciences (RCUS) had its price target raised by Wedbush from $37.00 to $41.00. They now have an "outperform" rating on the stock.
3/26
05:49 am
rcus
Arcus Biosciences (RCUS) was upgraded by Truist Financial Corporation to "strong-buy".
Low
Report
Arcus Biosciences (RCUS) was upgraded by Truist Financial Corporation to "strong-buy".
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/23
06:56 pm
rcus
Form 144 Arcus Biosciences, Inc. Filed by: Jarrett Jennifer
Low
Report
Form 144 Arcus Biosciences, Inc. Filed by: Jarrett Jennifer
4/21
04:09 pm
rcus
Form ARS Arcus Biosciences, Inc. For: Dec 31
Medium
Report
Form ARS Arcus Biosciences, Inc. For: Dec 31
4/21
04:08 pm
rcus
Form DEFA14A Arcus Biosciences, Inc.
Medium
Report
Form DEFA14A Arcus Biosciences, Inc.
4/21
04:07 pm
rcus
Form DEF 14A Arcus Biosciences, Inc. For: Jun 11
Medium
Report
Form DEF 14A Arcus Biosciences, Inc. For: Jun 11
4/20
07:57 am
rcus
Form 8-K Arcus Biosciences, Inc. For: Apr 20
Medium
Report
Form 8-K Arcus Biosciences, Inc. For: Apr 20
4/8
04:22 pm
rcus
Form 144 Arcus Biosciences, Inc. Filed by: Jarrett Jennifer
Low
Report
Form 144 Arcus Biosciences, Inc. Filed by: Jarrett Jennifer
3/26
03:46 pm
rcus
Form SCHEDULE 13G/A Arcus Biosciences, Inc. Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A Arcus Biosciences, Inc. Filed by: VANGUARD GROUP INC
3/23
07:46 am
rcus
Form 8-K Arcus Biosciences, Inc. For: Mar 17
Low
Report
Form 8-K Arcus Biosciences, Inc. For: Mar 17
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
9/26
Arcus Biosciences Inc (NYSE: RCUS) is now covered by analysts at Mizuho. They set a "buy" rating on the stock.
15.6%
2/18 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock. 12.7%
8/8 Arcus Biosciences Inc (NYSE: RCUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 11.0%
3/4 Arcus Biosciences Inc (NYSE: RCUS) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $24.00 price target on the stock. 7.7%
6/11 Arcus Biosciences to Provide a Mid-Year Update on Clinical and Preclinical Programs 6.4%
11/12 Arcus Biosciences Inc (NYSE: RCUS) is now covered by analysts at SunTrust Banks, Inc.. They set a "buy" rating on the stock. 5.4%
4/9 Arcus Biosciences Announces New Employment Inducement Grants 5.3%
12/18 Arcus Biosciences, in Collaboration with Genentech, Announces Two Randomized Clinical Studies to Advance AB928, a Dual Adenosine Receptor Antagonist, into Novel Combinations for Colorectal and Pancreatic Cancers 4.9%
10/30 Form 4 Arcus Biosciences, Inc. For: Oct 28 Filed by: Ribas Antoni 4.5%
7/4 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.25 price target on the stock. 4.4%
2/18 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $13.00 price target on the stock. 12.7%
8/8 Arcus Biosciences Inc (NYSE: RCUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 11.0%
3/4 Arcus Biosciences Inc (NYSE: RCUS) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $24.00 price target on the stock. 7.7%
6/11 Arcus Biosciences to Provide a Mid-Year Update on Clinical and Preclinical Programs 6.4%
11/12 Arcus Biosciences Inc (NYSE: RCUS) is now covered by analysts at SunTrust Banks, Inc.. They set a "buy" rating on the stock. 5.4%
4/9 Arcus Biosciences Announces New Employment Inducement Grants 5.3%
12/18 Arcus Biosciences, in Collaboration with Genentech, Announces Two Randomized Clinical Studies to Advance AB928, a Dual Adenosine Receptor Antagonist, into Novel Combinations for Colorectal and Pancreatic Cancers 4.9%
10/30 Form 4 Arcus Biosciences, Inc. For: Oct 28 Filed by: Ribas Antoni 4.5%
7/4 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.25 price target on the stock. 4.4%
TOP News Decliners
3/14
Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock.
-24.3%
2/25 Arcus Biosciences Inc (NYSE: RCUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.5%
11/25 Form 8-K/A Arcus Biosciences, Inc. For: Sep 10 -8.8%
4/7 Form 8-K Arcus Biosciences, Inc. For: Apr 07 -7.6%
11/7 Arcus Biosciences Inc (NYSE: RCUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.3%
10/4 Form 3 Arcus Biosciences, Inc. For: Oct 01 Filed by: Barker Jason -6.7%
4/16 Arcus stock jumps on Bloomberg News report that Gilead may take a stake [MarketWatch] -6.3%
3/3 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock. -5.3%
2/22 3 Biotech Stocks That Soared This Week: Are They Buys? [The Motley Fool] -5.1%
2/26 Arcus Biosciences Inc (NYSE: RCUS) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $22.00 price target on the stock. -4.8%
2/25 Arcus Biosciences Inc (NYSE: RCUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -9.5%
11/25 Form 8-K/A Arcus Biosciences, Inc. For: Sep 10 -8.8%
4/7 Form 8-K Arcus Biosciences, Inc. For: Apr 07 -7.6%
11/7 Arcus Biosciences Inc (NYSE: RCUS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.3%
10/4 Form 3 Arcus Biosciences, Inc. For: Oct 01 Filed by: Barker Jason -6.7%
4/16 Arcus stock jumps on Bloomberg News report that Gilead may take a stake [MarketWatch] -6.3%
3/3 Arcus Biosciences Inc (NYSE: RCUS) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock. -5.3%
2/22 3 Biotech Stocks That Soared This Week: Are They Buys? [The Motley Fool] -5.1%
2/26 Arcus Biosciences Inc (NYSE: RCUS) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $22.00 price target on the stock. -4.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: